Evaluating the Safety and Efficacy of Romiplostim (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)

Phase 2

Completed

• Conditions: Idiopathic Thrombocytopenic Purpura
• Interventions: Drug: Placebo; Drug: Romiplostim

• Registration Number: NCT00111475
• Lead Sponsor: Amgen

Brief Summary

The primary objective of this study is to evaluate the safety and tolerability of romiplostim in thrombocytopenic patients with ITP.

Detailed Description

Not available

Study Timeline

• Study Start: 2002-07-01
• Primary Completion: 2004-06-17
• Study Completion: 2004-06-17
• Study First Submitted: 2005-05-20
• Study First Submitted QC: 2005-05-20
• Study First Posted: 2005-05-23
• Results First Submitted: 2019-06-26
• Status Verified: 2019-12
• Results First Submitted QC: 2019-12-20
• Last Update Submitted: 2019-12-20
• Results First Posted: 2020-01-10
• Last Update Posted: 2020-01-10

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 45

Inclusion Criteria

• Diagnosis of ITP according to American Society of Hematology (ASH) guidelines at least 3 months before enrollment

• Have completed at least 1 prior treatment for ITP

• Two (including day -2) of the 3 platelet counts taken during the screening and pre-treatment periods must have fulfilled the following:

  • less than 30 x 10^9/L for those subjects not receiving any ITP therapy,
  • less than 50 x 10^9/L for those subjects receiving any ITP therapy

• Eastern Cooperative Oncology Group performance status of 0 to 2

• Serum creatinine concentration ≤ 2 mg/dL (≤ 176.8 µmol/L)

• Adequate liver function, as evidenced by a serum bilirubin ≤ 1.5 times the laboratory normal range

• Hemoglobin greater than 10.0 g/dL

• Written informed consent

Exclusion Criteria

• Considered a substantial risk for adverse outcomes because of a clinically important trend (as determined by the investigator) detected in the platelet counts during the screening period
• Any known history of bone marrow stem cell disorder
• Any active malignancy. If prior history of cancer other than basal cell carcinoma or cervical carcinoma in situ, no treatment or active disease within 5 years before randomization
• Documented diagnosis of arterial thrombosis (ie, stroke, transient ischemic attack, or myocardial infarction) in the previous year; history of venous thrombosis (ie, deep vein thrombosis, pulmonary embolism) and receiving anticoagulation therapy
• Unstable or uncontrolled disease or condition related to or impacting cardiac function (e.g., unstable angina, congestive heart failure [New York Heart Association (NYHA) greater than class II], uncontrolled hypertension [diastolic greater than 100 mmHg] or cardiac arrhythmia)
• Have 3 or more of the following predisposing factors for thromboembolic events: diabetes; smoker using oral contraceptives; hypercholesteremia (> 240 mg/dL); treatment for hypertension
• Known positive test for human immunodeficiency virus (HIV) infection or hepatitis C virus
• Received any treatment for ITP (except for a constant dose schedule of corticosteroids) within 4 weeks before the screening visit
• Received intravenous (IV) immunoglobulin (Ig) or WinRho within 2 weeks before the screening visit
• Received hematopoietic growth factors, including interleukin (IL)-11 (Neumega®) within 4 weeks before the screening visit
• Past or present participation in any study evaluating polyethylene glycol recombinant human magakaryopoiesis differentiating factor (PEG-rHuMGDF), recombinant human thrombopoietin (rHuTPO), or related platelet product
• Received any alkylating agents within 8 weeks before the screening visit or anticipated use during the time of the proposed study
• Received any monoclonal antibody (eg, rituximab) within 16 weeks before the screening visit or anticipated use during the time of the proposed study
• Less than 4 weeks since receipt of any therapeutic drug or device that is not FDA approved for any indication before the screening period
• Less than 2 months since major surgery (including laparoscopic splenectomy)
• Pregnant or breast feeding
• Subjects of reproductive potential who are not using adequate contraceptive precautions, in the judgment of the investigator

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SEQUENTIAL

Arm && Interventions

Group	Intervention	Description
Part B: Placebo	Placebo	Participants received placebo subcutaneously once a week for 6 weeks.
Part B: Romiplostim 3.0 µg/kg	Romiplostim	Participants received 3.0 µg/kg subcutaneously once a week for 6 weeks.
Part A: Romiplostim 0.5 µg/kg	Romiplostim	Participants received 0.5 µg/kg romiplostim subcutaneously on day 1 and day 15 or 22, depending on platelet counts.
Part A: Romiplostim 1.0 µg/kg	Romiplostim	Participants received 1.0 µg/kg romiplostim subcutaneously on day 1 and on day 15 or 22 depending on platelet counts.
Part A: Romiplostim 6 µg/kg	Romiplostim	Participants received 6.0 µg/kg romiplostim subcutaneously on day 1 and day 15 or 22, depending on platelet counts.
Part A: Romiplostim 3 µg/kg	Romiplostim	Participants received 3.0 µg/kg romiplostim subcutaneously on day 1 and day 15 or 22, depending on platelet counts.
Part A: Romiplostim 0.2 µg/kg	Romiplostim	Participants received 0.2 µg/kg romiplostim subcutaneously on day 1 and day 15 or 22, depending on platelet counts.
Part A: Romiplostim 10 µg/kg	Romiplostim	Participants received 10.0 µg/kg romiplostim subcutaneously on day 1 and day 15 or 22, depending on platelet counts.
Part B: Romiplostim 1.0 µg/kg	Romiplostim	Participants received 1.0 µg/kg subcutaneously once a week for 6 weeks.
Part B: Romiplostim 6.0 µg/kg	Romiplostim	Participants received 6.0 µg/kg subcutaneously once a week for 6 weeks.

Primary Outcome Measures

Name	Time	Method
Number of Participants With Adverse Events	From first dose of study drug through 8 weeks (Part A) or 6 weeks (Part B) after last dose of study drug; 78 days
Number of Participants With Anti-romiplostim or Anti-endogenous Thrombopoietin Neutralizing Antibodies	Assessed on day 29 (Part A only), day 43 (Part B only), and day 78	The development of antibodies to romiplostim or to endogenous thrombopoietin (eTPO) was assessed using a neutralizing bioassay. Participants positive for neutralizing antibodies at any of the assessments during the study are reported.

Secondary Outcome Measures

Name	Time	Method
Number of Participants With an Increase in Platelet Count of ≥ 20 x 10⁹ Cells/L Over Baseline in Part A	After first dose (day 1 to day 15 or 22), and after second dose (day 15 or 22 to day 78)	Platelet count data after the use of rescue medication were not included; participants with no platelet count data were considered non-responders.
Number of Participants With a Peak Platelet Count ≥ 100 x 10⁹ Cells/L in Part A	After first dose (day 1 to day 15 or 22) and after second dose (day 15 or 22 to day 78)	Platelet count data after the use of rescue medication were not included; participants with no platelet count data were considered non-responders.
Number of Participants Who Achieved Targeted Therapeutic Platelet Level in Part A	After first dose (day 1 to day 15 or 22) and after second dose (day 15 or 22 to day 78)	Targeted therapeutic platelet level was defined as a doubling of baseline platelet counts and between 50 to 450 x 10⁹ cells/L.; Platelet count data after the use of rescue medication were not included; participants with no platelet count data were considered non-responders.
Number of Participants With a Peak Platelet Count of > 450 x 10⁹ Cells/L in Part A	After first dose (day 1 to day 15 or 22) and after second dose (day 15 or 22 to day 78)	Platelet count data after the use of rescue medication were not included; participants with no platelet count data were considered non-responders.
Peak Platelet Count After Each Dose in Part A	After first dose (day 1 to day 15 or 22) and after second dose (day 15 or 22 to day 78)	Platelet count data after the use of rescue medication were not included.
Change From Baseline in Peak Platelet Count After Each Dose in Part A	Baseline and after first dose (day 1 to day 15 or 22) and after second dose (day 15 or 22 to day 78)	Platelet count data after the use of rescue medication were not included.
Time to Peak Platelet Count After Each Dose in Part A	After first dose (day 1 to day 15 or 22) and after second dose (day 15 or 22 to day 78)	Platelet count data after the use of rescue medication were not included.
Duration Within the Targeted Therapeutic Platelet Range In Part A	After first dose (day 1 to day 15 or 22) and after second dose (day 15 or 22 to day 78)	Targeted therapeutic platelet level was defined as a platelet count that was double the baseline level and ≥ 50 and ≤ 450 × 10⁹ cells/L.; Platelet count data after the use of rescue medication were not included.
Percentage of Participants Who Achieved Targeted Therapeutic Platelet Level In Part B	Day 1 to day 78	Targeted therapeutic platelet level was defined as a doubling of baseline platelet counts and within the range of greater than or equal to 50 x 10⁹ cells/L and less than or equal to 450 x 10⁹ cells/L.; Platelet count data after use of rescue medication were not included in the analysis.
Percentage of Participants With an Increase in Platelet Count of ≥ 20 x 10⁹ Cells/L Over Baseline in Part B	Day 1 to day 78	Platelet count data after administration of rescue medication were not included in the analysis. Participants with no platelet count data were considered non-responders.
Percentage of Participants With a Peak Platelet Count of ≥ 100 x 10⁹ Cells/L in Part B	Day 1 to day 78	Platelet count data after administration of rescue medication were not included in the analysis. Participants with no platelet count data were considered non-responders.
Percentage of Participants With a Peak Platelet Count of > 450 x 10⁹ Cells/L in Part B	Day 1 to day 78	Platelet count data after administration of rescue medication were not included in the analysis. Participants with no platelet count data were considered non-responders.
Percentage of Participants With a Peak Platelet Count of > 500 x 10⁹ Cells/L in Part B	Day 1 to day 78	Platelet count data after administration of rescue medication were not included in the analysis. Participants with no platelet count data were considered non-responders.
Peak Platelet Count in Part B	Day 1 to day 78	Platelet count data after administration of rescue medication were not included in the analysis.
Change From Baseline in Peak Platelet Count in Part B	Baseline and day 1 to day 78	Platelet count data after administration of rescue medication were not included in the analysis.
Time to Peak Platelet Count in Part B	Day 1 to day 78	Platelet count data after administration of rescue medication were not included in the analysis. Time to peak platelet count was analyzed using the Kaplan-Meier method.
Duration Within the Targeted Therapeutic Platelet Range in Part B	Day 1 to day 78	Targeted therapeutic platelet level was defined as a doubling of baseline platelet counts and within the range of greater than or equal to 50 × 10⁹ cells/L and less than or equal to 450 × 10⁹ cells/L.; Platelet count data after administration of rescue medication were not included in the analysis.